Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492895 | 1.00 | OPRM1 (0.41) | OPRM1HRH3ALDH1A1PPM1BPTPN1 | |
| Hydrochloric Acid SCHEMBL31599756 | 0.98 | OPRM1 (0.40) | OPRM1HRH3ALDH1A1PPM1BPTPN1 | |
| SCHEMBL17390200 | 0.90 | OPRM1 (0.36) | OPRM1ALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL1634121 | 0.84 | ALDH1A1 (0.46) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL16369922 | 0.84 | ALDH1A1 (0.43) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL1635627 | 0.82 | ALDH1A1 (0.49) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL14699452 | 0.82 | CYP3A4 (0.38) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL1634763 | 0.82 | ALDH1A1 (0.49) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL1634765 | 0.82 | ALDH1A1 (0.49) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL16985036 | 0.81 | ALDH1A1 (0.37) | OPRM1ALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3099694-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-16 | — | — | EP | disclosed |
| US-9815841-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| US-20170022204-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-26 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| WO-2016021562-A1 | CYANOTHIOPHENE DERIVATIVE | キッセイ薬品工業株式会社 | 2016-02-11 | — | — | WO | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| WO-2012047703-A2 | CYCLOPROPYL-SPIRO-PIPERIDINES USEFUL AS SODIUM CHANNEL BLOCKERS | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047703-A2 | CYCLOPROPYL-SPIRO-PIPERIDINES USEFUL AS SODIUM CHANNEL BLOCKERS | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| WO-2008147314-A1 | SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | OPRM1 2065/4885HRH3 4710/4885ALDH1A1 307/4885 |
| US-20100168105-A1 | Spirocyclopropyl Piperidine Derivatives | HRH3, HRH2, HRH4 | OPRM1 95/4885HRH3 1/4885ALDH1A1 685/4885 |
| US-20170022204-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | OPRM1 2945/4885HRH3 2368/4885ALDH1A1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.